JiangXi Tianxin Pharmaceutical Past Earnings Performance
Past criteria checks 3/6
JiangXi Tianxin Pharmaceutical's earnings have been declining at an average annual rate of -12.6%, while the Personal Products industry saw earnings growing at 6.4% annually. Revenues have been declining at an average rate of 4.4% per year. JiangXi Tianxin Pharmaceutical's return on equity is 12.5%, and it has net margins of 27.8%.
Key information
-12.6%
Earnings growth rate
-15.7%
EPS growth rate
| Personal Products Industry Growth | 7.8% |
| Revenue growth rate | -4.4% |
| Return on equity | 12.5% |
| Net Margin | 27.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
JiangXi Tianxin Pharmaceutical's (SHSE:603235) Earnings Are Built On Soft Foundations
Nov 05
JiangXi Tianxin Pharmaceutical's (SHSE:603235) Weak Earnings May Only Reveal A Part Of The Whole Picture
May 06Recent updates
JiangXi Tianxin Pharmaceutical's (SHSE:603235) Earnings Are Built On Soft Foundations
Nov 05We Think JiangXi Tianxin Pharmaceutical (SHSE:603235) Can Stay On Top Of Its Debt
Aug 23JiangXi Tianxin Pharmaceutical's (SHSE:603235) Weak Earnings May Only Reveal A Part Of The Whole Picture
May 06Does JiangXi Tianxin Pharmaceutical (SHSE:603235) Have A Healthy Balance Sheet?
Apr 24Revenue & Expenses Breakdown
How JiangXi Tianxin Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,008 | 557 | 173 | 122 |
| 30 Jun 24 | 1,828 | 491 | 167 | 119 |
| 31 Mar 24 | 1,798 | 515 | 162 | 119 |
| 31 Dec 23 | 1,882 | 476 | 168 | 112 |
| 30 Sep 23 | 2,042 | 484 | 170 | 91 |
| 30 Jun 23 | 2,184 | 551 | 170 | 91 |
| 31 Mar 23 | 2,277 | 553 | 172 | 90 |
| 31 Dec 22 | 2,305 | 622 | 171 | 89 |
| 30 Sep 22 | 2,378 | 713 | 160 | 78 |
| 30 Jun 22 | 2,496 | 725 | 157 | 72 |
| 31 Mar 22 | 2,488 | 716 | 149 | 62 |
| 31 Dec 21 | 2,522 | 744 | 147 | 59 |
| 31 Dec 20 | 2,304 | 887 | 129 | 49 |
| 31 Dec 19 | 2,025 | 728 | 146 | 48 |
| 31 Dec 18 | 2,578 | 1,098 | 257 | 44 |
Quality Earnings: 603235 has a high level of non-cash earnings.
Growing Profit Margin: 603235's current net profit margins (27.8%) are higher than last year (23.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603235's earnings have declined by 12.6% per year over the past 5 years.
Accelerating Growth: 603235's earnings growth over the past year (15.2%) exceeds its 5-year average (-12.6% per year).
Earnings vs Industry: 603235 earnings growth over the past year (15.2%) exceeded the Personal Products industry -10.1%.
Return on Equity
High ROE: 603235's Return on Equity (12.5%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 08:55 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
JiangXi Tianxin Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|